366 related articles for article (PubMed ID: 28502721)
1. MET Exon 14 Skipping Mutations in Lung Adenocarcinoma: Clinicopathologic Implications and Prognostic Values.
Lee GD; Lee SE; Oh DY; Yu DB; Jeong HM; Kim J; Hong S; Jung HS; Oh E; Song JY; Lee MS; Kim M; Jung K; Kim J; Shin YK; Choi YL; Kim HR
J Thorac Oncol; 2017 Aug; 12(8):1233-1246. PubMed ID: 28502721
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
Gow CH; Hsieh MS; Wu SG; Shih JY
Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
[TBL] [Abstract][Full Text] [Related]
3. Responses to the multitargeted MET/ALK/ROS1 inhibitor crizotinib and co-occurring mutations in lung adenocarcinomas with MET amplification or MET exon 14 skipping mutation.
Jorge SE; Schulman S; Freed JA; VanderLaan PA; Rangachari D; Kobayashi SS; Huberman MS; Costa DB
Lung Cancer; 2015 Dec; 90(3):369-74. PubMed ID: 26791794
[TBL] [Abstract][Full Text] [Related]
4. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
5. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
6. Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib.
Wang SXY; Zhang BM; Wakelee HA; Koontz MZ; Pan M; Diehn M; Kunder CA; Neal JW
Anticancer Drugs; 2019 Jun; 30(5):537-541. PubMed ID: 30762593
[TBL] [Abstract][Full Text] [Related]
7. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of
Yu Y; Zhang Q; Zhang J; Lu S
J Cancer Res Ther; 2019; 15(4):909-913. PubMed ID: 31436251
[TBL] [Abstract][Full Text] [Related]
9. Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies.
Wu YL; Smit EF; Bauer TM
Cancer Treat Rev; 2021 Apr; 95():102173. PubMed ID: 33740553
[TBL] [Abstract][Full Text] [Related]
10. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
11. MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.
Mazieres J; Vioix H; Pfeiffer BM; Campden RI; Chen Z; Heeg B; Cortot AB
Clin Lung Cancer; 2023 Sep; 24(6):483-497. PubMed ID: 37451931
[TBL] [Abstract][Full Text] [Related]
12. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring
Le X; Hong L; Hensel C; Chen R; Kemp H; Coleman N; Ciunci CA; Liu SV; Negrao MV; Yen J; Xia X; Scheuenpflug J; Stroh C; Juraeva D; Tsao A; Hong D; Raymond V; Paik P; Zhang J; Heymach JV
JCO Precis Oncol; 2021; 5():. PubMed ID: 34957368
[TBL] [Abstract][Full Text] [Related]
13. Potent antitumor activity of ensartinib in MET exon 14 skipping-mutated non-small cell lung cancer.
Xia Y; Jin R; Li M; Lan F; Zhu H; Yu Y; Miao D; Wang Q; Zhou Y; Selvaggi G; Ying S; Zhang J; Shen H; Le X; Li W
Cancer Lett; 2023 May; 561():216140. PubMed ID: 36948240
[TBL] [Abstract][Full Text] [Related]
14. Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.
Rotow JK; Gui P; Wu W; Raymond VM; Lanman RB; Kaye FJ; Peled N; Fece de la Cruz F; Nadres B; Corcoran RB; Yeh I; Bastian BC; Starostik P; Newsom K; Olivas VR; Wolff AM; Fraser JS; Collisson EA; McCoach CE; Camidge DR; Pacheco J; Bazhenova L; Li T; Bivona TG; Blakely CM
Clin Cancer Res; 2020 Jan; 26(2):439-449. PubMed ID: 31548343
[TBL] [Abstract][Full Text] [Related]
15. Genetic screening and molecular characterization of MET alterations in non-small cell lung cancer.
Saigi M; McLeer-Florin A; Pros E; Nadal E; Brambilla E; Sanchez-Cespedes M
Clin Transl Oncol; 2018 Jul; 20(7):881-888. PubMed ID: 29139039
[TBL] [Abstract][Full Text] [Related]
16. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.
Watari N; Yamaguchi K; Terada H; Hamai K; Masuda K; Nishimura Y; Sakamoto S; Masuda T; Horimasu Y; Miyamoto S; Nakashima T; Iwamoto H; Shoda H; Ishikawa N; Fujitaka K; Miyazaki K; Miyata Y; Hamada H; Awai K; Hattori N
BMC Pulm Med; 2022 Jun; 22(1):260. PubMed ID: 35773658
[TBL] [Abstract][Full Text] [Related]
17. Highly accurate DNA-based detection and treatment results of MET exon 14 skipping mutations in lung cancer.
Pruis MA; Geurts-Giele WRR; von der TJH; Meijssen IC; Dinjens WNM; Aerts JGJV; Dingemans AMC; Lolkema MP; Paats MS; Dubbink HJ
Lung Cancer; 2020 Feb; 140():46-54. PubMed ID: 31862577
[TBL] [Abstract][Full Text] [Related]
18. An improved assay for detection of theranostic gene translocations and MET exon 14 skipping in thoracic oncology.
Piton N; Lanic MD; Marguet F; Lamy A; Blanchard F; Guisier F; Viennot M; Salaün M; Thiberville L; Jardin F; Sabourin JC; Ruminy P
Lab Invest; 2021 May; 101(5):648-660. PubMed ID: 33495574
[TBL] [Abstract][Full Text] [Related]
19. Responses to crizotinib and cabozantinib in patient with lung adenocarcinoma harboring mesenchymal-epithelial transition factor exon 14 skipping mutation: A case report.
Qin RY; Liu LS; Zhang HY; Lu CH; Guo XY; Zhang LY; Yuan XB; Xue HH
Medicine (Baltimore); 2021 Jan; 100(4):e24300. PubMed ID: 33530219
[TBL] [Abstract][Full Text] [Related]
20. MET IHC Is a Poor Screen for MET Amplification or MET Exon 14 Mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
Guo R; Berry LD; Aisner DL; Sheren J; Boyle T; Bunn PA; Johnson BE; Kwiatkowski DJ; Drilon A; Sholl LM; Kris MG
J Thorac Oncol; 2019 Sep; 14(9):1666-1671. PubMed ID: 31228623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
